**
Individuals in the UK suffering from hypermobility conditions endure extraordinarily lengthy waits—sometimes stretching to 21 years—for a diagnosis, according to a comprehensive study led by researchers at the University of Edinburgh. This research, which surveyed over 2,000 participants, sheds light on the critical lack of awareness surrounding hypermobility spectrum disorders (HSD) and hypermobile Ehlers-Danlos syndrome (hEDS) among healthcare professionals, leaving many patients grappling with chronic symptoms in silence.
A Hidden Struggle: The Reality of Hypermobile Disorders
Hypermobility conditions, including hEDS and HSD, significantly impact the connective tissue throughout the body, leading to a variety of debilitating symptoms such as chronic pain, joint instability, and fatigue. The study highlights a grim reality: patients often experience fragmented healthcare, which can severely affect their mental health, education, and employment prospects.
Notably, the research revealed that nearly half of the participants were unemployed, with 46% relying on disability-related benefits. Additionally, more than half reported disruptions in their educational journeys, underscoring the far-reaching consequences of delayed diagnoses.
The Personal Toll: Voices from Those Affected
The challenges faced by individuals with hypermobility disorders are not merely statistical; they resonate on a deeply personal level. Prominent figures like actress and director Lena Dunham have shared their experiences of living with hEDS. In her recent book, “Famesick,” Dunham recounted how she dismissed her myriad symptoms—from migraines to fainting spells—as mere quirks until a proper diagnosis in her late 20s. Her story exemplifies the broader issue of how women’s pain is often overlooked, leading to prolonged suffering without recognition.
The Diagnostic Journey: A Long and Winding Road
The study’s findings reveal a staggering average wait time for diagnosis that varies across the UK. Those in Wales reported the longest journey, averaging 21.7 years, followed closely by Northern Ireland at 21.1 years. Scotland and England also experienced long waits, with averages of 19.5 and 19 years, respectively. This prolonged process often forces patients to seek diagnoses in other regions, with more than a third of Welsh and Northern Irish respondents travelling elsewhere in the UK for care.
The researchers emphasised the need for a more streamlined approach to diagnosis and treatment, stating that equitable and multidisciplinary care pathways are essential to address the complex nature of these conditions. Kathryn Berg, trial and data manager at the university’s Institute of Genetics and Cancer, remarked, “Our findings show the urgent need for equitable, multidisciplinary care pathways that recognise the complex and multisystemic nature of these conditions.”
Recognising the Issue: Response from Health Authorities
In response to the study’s findings, both Welsh and UK government representatives acknowledged the challenges faced by those with hypermobility disorders. A spokesperson for the Welsh government noted the long and complicated journeys to diagnosis and expressed intentions to endorse a “draft community health pathway” aimed at improving access to specialist care.
Meanwhile, a spokesperson for the UK government stated, “People living with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders deserve to have their symptoms recognised and taken seriously.” The government has introduced a toolkit developed by the Royal College of General Practitioners in collaboration with EDS Support UK, designed to enhance clinician awareness and improve the consistency of care for these complex conditions.
Why it Matters
The staggering wait times for diagnosis and treatment of hypermobility disorders in the UK not only highlight a pressing healthcare issue but also reflect broader societal attitudes towards chronic pain, particularly in women. The findings call for immediate action to improve awareness and care pathways for those affected. By addressing these gaps, we can foster a healthcare system that truly values and prioritises the health and well-being of all its patients, ensuring that no one suffers in silence.